Loading financial data...

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Financial Statements | Global Financial Data

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVASEC EDGAR

Pharmaceutical Preparations(L3)CIK: 818686

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$15.8B	$14.9B	$15.9B	$16.7B	$16.9B
Cost of Goods and Services Sold	$8.2B	$8.0B	$8.3B	$8.9B	$9.4B
Gross Profit	$7.6B	$7.0B	$7.6B	$7.7B	$7.5B
Research and Development Expense	—	—	—	$98.0M	—
Operating Income (Loss)	$433.0M	-$2.2B	$1.7B	-$3.6B	-$443.0M
Interest Expense	$1.0B	$930.0M	$891.0M	$901.0M	$822.0M
Nonoperating Income (Expense)	-$1.1B	-$966.0M	-$1.1B	-$834.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$39.3B	$43.5B	$45.9B	$47.7B	$50.6B
Assets, Current	$12.6B	$12.5B	$12.1B	$12.6B	$13.0B
Cash and Cash Equivalents, at Carrying Value	$3.2B	$2.8B	$2.2B	$2.2B	$2.0B
Accounts Receivable, after Allowance for Credit Loss, Current	$3.1B	$3.4B	$3.7B	$4.5B	$4.6B
Inventory, Net	$3.0B	$4.0B	$3.8B	$3.8B	$4.4B
Liabilities	$33.6B	$35.4B	$36.1B	$36.4B	$39.6B
Liabilities, Current	$12.8B	$12.2B	$11.5B	$11.0B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$1.4B	$1.6B	$798.0M	$1.2B	$748.0M
Net Cash Provided by (Used in) Investing Activities	$968.0M	$656.0M	$1.5B	$863.0M	$1.4B
Net Cash Provided by (Used in) Financing Activities	-$1.9B	-$1.5B	-$2.2B	-$1.9B	-$1.9B
Payments to Acquire Property, Plant, and Equipment	—	—	—	$578.0M	$525.0M
Payments of Dividends	—	—	—	—	—
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)